[{"id":"11f1db6a-6822-4ad4-9456-501ec049e598","acronym":"BEND-MBEC","url":"https://clinicaltrials.gov/study/NCT07189702","created_at":"2025-09-27T08:41:02.423Z","updated_at":"2025-09-27T08:41:02.423Z","phase":"","brief_title":"Plant-Based Nutrition for Breast or Endometrial Cancer","source_id_and_acronym":"NCT07189702 - BEND-MBEC","lead_sponsor":"University of Rochester","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/01/2025","start_date":" 12/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2025-09-24"},{"id":"f0b2108a-611c-4070-92fc-407c3cf54f4d","acronym":"SIGMA","url":"https://clinicaltrials.gov/study/NCT07151807","created_at":"2025-09-06T13:42:25.722Z","updated_at":"2025-09-06T13:42:25.722Z","phase":"","brief_title":"Serum IGF-1 and IGF-1Ec in Malignancy Assessment","source_id_and_acronym":"NCT07151807 - SIGMA","lead_sponsor":"Çanakkale Onsekiz Mart University","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/01/2025","start_date":" 04/01/2025","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-09-03"},{"id":"c13b4cf9-274e-41ee-98c2-c2c6b58c5ea0","acronym":"","url":"https://clinicaltrials.gov/study/NCT07065552","created_at":"2025-07-19T14:15:38.690Z","updated_at":"2025-07-19T14:15:38.690Z","phase":"Phase 1","brief_title":"Tirzepatide in Obesity-Driven Endometrial Cancer","source_id_and_acronym":"NCT07065552","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-07-15"},{"id":"2d035165-64ed-42fd-8dd4-3556c0edcbcd","acronym":"NCI-2018-01593","url":"https://clinicaltrials.gov/study/NCT03637816","created_at":"2025-06-07T14:41:51.112Z","updated_at":"2025-06-07T14:41:51.112Z","phase":"Phase 1","brief_title":"Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03637816 - NCI-2018-01593","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CXCL8 • IGF1 • IL6R","pipe":"","alterations":" ","tags":["CXCL8 • IGF1 • IL6R"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 11/27/2018","start_date":" 11/27/2018","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-06-04"},{"id":"3633dcfa-95c2-4d04-aaa1-efcdb653ee34","acronym":"","url":"https://clinicaltrials.gov/study/NCT02555176","created_at":"2025-09-06T19:01:30.890Z","updated_at":"2025-09-06T19:01:30.890Z","phase":"","brief_title":"Low-Carbohydrate Normocaloric Diet in Patients With Head and Neck Carcinoma (HNC)","source_id_and_acronym":"NCT02555176","lead_sponsor":"Sidney Kimmel Cancer Center at Thomas Jefferson University","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 12/14/2016","start_date":" 12/14/2016","primary_txt":" Primary completion: 01/01/2017","primary_completion_date":" 01/01/2017","study_txt":" Completion: 10/01/2018","study_completion_date":" 10/01/2018","last_update_posted":"2025-05-20"},{"id":"faecb63e-ceb1-42d4-81de-58e59c1de21c","acronym":"KETOACRO","url":"https://clinicaltrials.gov/study/NCT06949891","created_at":"2025-09-07T01:25:58.833Z","updated_at":"2025-09-07T01:25:58.833Z","phase":"","brief_title":"KETOgenic Diet Therapy in Patients With ACROmegaly","source_id_and_acronym":"NCT06949891 - KETOACRO","lead_sponsor":"Erasmus Medical Center","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-04-29"},{"id":"1d6d3022-d558-4449-be88-cf113b4fe994","acronym":"","url":"https://clinicaltrials.gov/study/NCT06603155","created_at":"2025-02-25T20:22:11.081Z","updated_at":"2025-02-25T20:22:11.081Z","phase":"","brief_title":"Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC)","source_id_and_acronym":"NCT06603155","lead_sponsor":"Duke University","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 02/01/2025","start_date":" 02/01/2025","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-01-14"},{"id":"9cbf2f0f-79e3-4928-a4ed-5ed00dfa5bc5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06713993","created_at":"2025-02-26T10:41:48.420Z","updated_at":"2025-02-26T10:41:48.420Z","phase":"","brief_title":"Semmelweis Esophageal Cancer Study: Noninvasive Prognostic Parameters in Patients With Oesophageal and Esophagogastric Junction Cancer","source_id_and_acronym":"NCT06713993","lead_sponsor":"Semmelweis University","biomarkers":" IL6 • GDF15 • IGF1","pipe":"","alterations":" ","tags":["IL6 • GDF15 • IGF1"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/10/2024","start_date":" 09/10/2024","primary_txt":" Primary completion: 09/30/2029","primary_completion_date":" 09/30/2029","study_txt":" Completion: 09/10/2034","study_completion_date":" 09/10/2034","last_update_posted":"2024-12-03"},{"id":"b512d1ec-5eed-4af0-ad6e-074e6046eff9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06540612","created_at":"2025-02-27T08:02:01.646Z","updated_at":"2025-02-27T08:02:01.646Z","phase":"","brief_title":"Effects of Aerobic Exercise on Cancer-Related Biomarkers, Functional Capacity, Cognitive Status and Quality of Life in Women With Breast Cancer","source_id_and_acronym":"NCT06540612","lead_sponsor":"Hasan Kalyoncu University","biomarkers":" IL6 • TNFA • IGF1 • LEP","pipe":"","alterations":" ","tags":["IL6 • TNFA • IGF1 • LEP"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 69","initiation":"Initiation: 05/15/2024","start_date":" 05/15/2024","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 08/15/2025","study_completion_date":" 08/15/2025","last_update_posted":"2024-08-09"},{"id":"783af00c-8819-44e7-853c-84a6cd6fe0d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06386887","created_at":"2024-04-26T19:53:09.235Z","updated_at":"2024-07-02T16:34:26.415Z","phase":"","brief_title":"Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer","source_id_and_acronym":"NCT06386887","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/31/2024","start_date":" 07/31/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-06-13"},{"id":"853b2c7a-ae04-4c10-89b6-0e2751505bec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04812652","created_at":"2024-05-04T04:26:52.545Z","updated_at":"2024-07-02T16:35:06.634Z","phase":"","brief_title":"Digitally Distributed Yoga for Women Treated for Breast Cancer","source_id_and_acronym":"NCT04812652","lead_sponsor":"Region Örebro County","biomarkers":" TNFA • CXCL8 • IGF1 • IGF2 • IL1B • LEP","pipe":"","alterations":" ","tags":["TNFA • CXCL8 • IGF1 • IGF2 • IL1B • LEP"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 229","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-05-01"},{"id":"2abc8b5e-bbff-4610-b944-f367032e5447","acronym":"","url":"https://clinicaltrials.gov/study/NCT06156020","created_at":"2023-12-09T16:35:00.738Z","updated_at":"2024-07-02T16:35:13.394Z","phase":"","brief_title":"Outcome Analysis of Endoscopic Resection of Pituitary Adenomas","source_id_and_acronym":"NCT06156020","lead_sponsor":"National Cheng-Kung University Hospital","biomarkers":" IGF1 • PRL","pipe":"","alterations":" ","tags":["IGF1 • PRL"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 01/01/2020","start_date":" 01/01/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-21"},{"id":"7c89998c-ad05-46fc-b5b5-f616ad2f3924","acronym":"","url":"https://clinicaltrials.gov/study/NCT01614990","created_at":"2021-01-18T06:55:08.185Z","updated_at":"2024-07-02T16:35:13.819Z","phase":"Phase 2","brief_title":"Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia","source_id_and_acronym":"NCT01614990","lead_sponsor":"Garcia, Jose M., MD, PhD","biomarkers":" IL6 • IGF1 • IGFBP3","pipe":"","alterations":" ","tags":["IL6 • IGF1 • IGFBP3"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 05/01/2012","start_date":" 05/01/2012","primary_txt":" Primary completion: 07/01/2020","primary_completion_date":" 07/01/2020","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2024-03-20"},{"id":"0170dcd4-c22d-42e8-a253-3a55399779ea","acronym":"AAML1921","url":"https://clinicaltrials.gov/study/NCT04258943","created_at":"2023-12-14T16:16:46.995Z","updated_at":"2025-02-25T16:25:40.949Z","phase":"Phase 1/2","brief_title":"Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia","source_id_and_acronym":"NCT04258943 - AAML1921","lead_sponsor":"Children's Oncology Group","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bosutinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/06/2020","start_date":" 04/06/2020","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2024-02-22"},{"id":"f1bf7f47-5eb8-4967-88d5-00eb9911f656","acronym":"FAST","url":"https://clinicaltrials.gov/study/NCT05990426","created_at":"2023-11-13T16:14:40.904Z","updated_at":"2024-07-02T16:35:29.446Z","phase":"","brief_title":"Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy","source_id_and_acronym":"NCT05990426 - FAST","lead_sponsor":"Northwestern University","biomarkers":" IGF1 • IGFBP1","pipe":"","alterations":" ","tags":["IGF1 • IGFBP1"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/16/2023","start_date":" 10/16/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2023-11-13"},{"id":"7fdea8a8-d91d-4bae-b450-4ec22054decf","acronym":"MoviS","url":"https://clinicaltrials.gov/study/NCT04818359","created_at":"2021-03-26T14:52:27.319Z","updated_at":"2024-07-02T16:35:29.823Z","phase":"","brief_title":"Movement and Health Beyond Care (MoviS)","source_id_and_acronym":"NCT04818359 - MoviS","lead_sponsor":"University of Urbino \"Carlo Bo\"","biomarkers":" IGF1 • CRP","pipe":"","alterations":" ","tags":["IGF1 • CRP"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 172","initiation":"Initiation: 01/07/2020","start_date":" 01/07/2020","primary_txt":" Primary completion: 05/31/2024","primary_completion_date":" 05/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-11-09"},{"id":"303ded59-2b91-4419-83f0-79853c57158c","acronym":"TEAS","url":"https://clinicaltrials.gov/study/NCT05482477","created_at":"2022-08-01T14:54:42.639Z","updated_at":"2024-07-02T16:35:30.418Z","phase":"","brief_title":"Timing of Transcutaneous Acupoint Electrical Stimulation on Postoperative Recovery in Geriatric Patients With Gastrointestinal Tumor","source_id_and_acronym":"NCT05482477 - TEAS","lead_sponsor":"Subei People's Hospital of Jiangsu Province","biomarkers":" IL6 • IGF1 • CRP","pipe":"","alterations":" ","tags":["IL6 • IGF1 • CRP"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 238","initiation":"Initiation: 01/01/2024","start_date":" 01/01/2024","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2023-11-03"},{"id":"bbbbde50-86df-4089-8d78-2db1a196b549","acronym":"MMF","url":"https://clinicaltrials.gov/study/NCT03971591","created_at":"2021-01-18T19:32:17.276Z","updated_at":"2024-07-02T16:35:32.558Z","phase":"","brief_title":"Men Moving Forward: A Lifestyle Program for African-American Prostate Cancer Survivors","source_id_and_acronym":"NCT03971591 - MMF","lead_sponsor":"Medical College of Wisconsin","biomarkers":" IL6 • IGF1 • LEP","pipe":"","alterations":" ","tags":["IL6 • IGF1 • LEP"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 06/01/2019","start_date":" 06/01/2019","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2023-10-19"},{"id":"eba29365-719c-4084-a482-6d1de994a799","acronym":"COG-ACNS0334","url":"https://clinicaltrials.gov/study/NCT00336024","created_at":"2021-01-18T01:09:40.733Z","updated_at":"2024-07-02T16:35:35.818Z","phase":"Phase 3","brief_title":"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma","source_id_and_acronym":"NCT00336024 - COG-ACNS0334","lead_sponsor":"Children's Oncology Group","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • cyclophosphamide • etoposide IV • methotrexate • vincristine • leucovorin calcium • thiotepa • Neupogen (filgrastim) • cyclophosphamide intravenous • methotrexate IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 91","initiation":"Initiation: 08/06/2007","start_date":" 08/06/2007","primary_txt":" Primary completion: 12/31/2016","primary_completion_date":" 12/31/2016","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2023-09-25"},{"id":"e136e00d-6529-46cd-8f05-4924698557e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04170335","created_at":"2021-01-18T20:20:42.902Z","updated_at":"2024-07-02T16:35:36.890Z","phase":"","brief_title":"Effects of Bariatric Surgery on Breast Density Improvement and Impact on Breast Cancer Risk in Severe Obese Patients","source_id_and_acronym":"NCT04170335","lead_sponsor":"The Cleveland Clinic","biomarkers":" IL6 • TNFA • IGF1 • CRP","pipe":"","alterations":" ","tags":["IL6 • TNFA • IGF1 • CRP"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/22/2021","start_date":" 02/22/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-09-15"},{"id":"b7eeda1c-4953-4b53-929a-d79044662260","acronym":"CCTG MA32","url":"https://clinicaltrials.gov/study/NCT01101438","created_at":"2021-01-18T04:21:28.818Z","updated_at":"2024-07-02T16:35:37.413Z","phase":"Phase 3","brief_title":"A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer","source_id_and_acronym":"NCT01101438 - CCTG MA32","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" HER-2 • PGR • IGF1","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • HER-2 negative","tags":["HER-2 • PGR • IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Completed","enrollment":" Enrollment 3649","initiation":"Initiation: 08/13/2010","start_date":" 08/13/2010","primary_txt":" Primary completion: 09/21/2021","primary_completion_date":" 09/21/2021","study_txt":" Completion: 08/18/2023","study_completion_date":" 08/18/2023","last_update_posted":"2023-09-12"},{"id":"630319d6-7476-4345-9ba2-bdb41e52946d","acronym":"BWEL","url":"https://clinicaltrials.gov/study/NCT02750826","created_at":"2021-01-18T13:28:41.714Z","updated_at":"2024-07-02T16:35:38.388Z","phase":"Phase 3","brief_title":"Breast Cancer WEight Loss Study (BWEL Study)","source_id_and_acronym":"NCT02750826 - BWEL","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" HER-2 • ER • PGR • IL6 • TNFA • IGF1 • IGFBP3 • LEP","pipe":" | ","alterations":" HER-2 positive • HR positive • PGR positive","tags":["HER-2 • ER • PGR • IL6 • TNFA • IGF1 • IGFBP3 • LEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • PGR positive"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3177","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 05/01/2030","primary_completion_date":" 05/01/2030","study_txt":"","study_completion_date":"","last_update_posted":"2023-08-31"},{"id":"a1bef58e-86d0-4a4c-8e69-93297872915f","acronym":"QLARITY","url":"https://clinicaltrials.gov/study/NCT03749109","created_at":"2021-01-18T18:23:01.954Z","updated_at":"2024-07-02T16:35:40.789Z","phase":"Phase 2","brief_title":"Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis","source_id_and_acronym":"NCT03749109 - QLARITY","lead_sponsor":"Ferring Pharmaceuticals","biomarkers":" IGF1 • PRL","pipe":"","alterations":" ","tags":["IGF1 • PRL"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 08/19/2019","start_date":" 08/19/2019","primary_txt":" Primary completion: 06/21/2021","primary_completion_date":" 06/21/2021","study_txt":" Completion: 07/18/2021","study_completion_date":" 07/18/2021","last_update_posted":"2023-08-07"},{"id":"750b7ee3-4e40-4985-b4dc-c8121bce3433","acronym":"","url":"https://clinicaltrials.gov/study/NCT05376709","created_at":"2022-05-17T12:54:18.073Z","updated_at":"2024-07-02T16:35:41.878Z","phase":"","brief_title":"A Mixed Methods Study of Nutrition Practice in Cancer Care on Non-Hodgkin Lymphoma Population","source_id_and_acronym":"NCT05376709","lead_sponsor":"National Taiwan University Hospital","biomarkers":" IGF1 • CRP","pipe":"","alterations":" ","tags":["IGF1 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2023-07-27"}]